BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Yoshitaka Arase, Tatehiro Kagawa, Kota Tsuruya, Hirohiko Sato, Erika Teramura, Kazuya Anzai, Shunji Hirose, Ryuzo Deguchi, Koichi Shiraishi, Tetsuya Mine. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory AscitesClinical Drug Investigation 2019; 39(1): 45 doi: 10.1007/s40261-018-0714-5
2
Maiko Namba, Akira Hiramatsu, Hiroshi Aikata, Kenichiro Kodama, Shinsuke Uchikawa, Kazuki Ohya, Kei Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Michio Imamura, Kazuaki Chayama. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosisJournal of Gastroenterology 2019;  doi: 10.1007/s00535-019-01623-4
3
Masayuki Miyazaki, Masayoshi Yada, Kosuke Tanaka, Takeshi Senjyu, Takeshi Goya, Kenta Motomura, Motoyuki Kohjima, Masaki Kato, Akihide Masumoto, Kazuhiro Kotoh. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinomaWorld Journal of Gastroenterology 2017; 23(29): 5379-5385 doi: 10.3748/wjg.v23.i29.5379
4
Ioannis Bellos, Konstantinos Kontzoglou, Despina N Perrea. Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysisJournal of Gastroenterology and Hepatology 2019;  doi: 10.1111/jgh.14784
5
Yoshitaka Takuma, Hirokazu Miyatake, Shota Iwadou, Shuji Uematsu, Ryouichi Okamoto, Yasuyuki Araki. Predictive factors for the effectiveness of tolvaptan in liver cirrhosis patients with refractory ascitesKanzo 2016; 57(12): 684 doi: 10.2957/kanzo.57.684
6
Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Noritomo Shimada, Toru Asano, Tadashi Ikegami, Mai Koeda, Tomomi Okubo, Taeang Arai, Ai Nakagawa-Iwashita, Yuji Yoshida, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Yoshimichi Chuganji, Yasushi Matsuzaki, Katsuhiko Iwakiri. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edemaJournal of Gastroenterology and Hepatology 2018; 33(6): 1256 doi: 10.1111/jgh.14047
7
Tomomi Kogiso, Takaomi Sagawa, Kazuhisa Kodama, Makiko Taniai, Katsutoshi Tokushige. Impact of continued administration of tolvaptan on cirrhotic patients with ascitesBMC Pharmacology and Toxicology 2018; 19(1) doi: 10.1186/s40360-018-0277-3